Summary
1.25 0.01(0.40%)07/01/2024
Assertio Therapeutics Inc (ASRT)
Assertio Therapeutics Inc (ASRT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.40 | 15.58 | 40.00 | 39.16 | 21.36 | -74.69 | 0.00 | -93.88 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.25 | |
| Open | 1.24 | |
| High | 1.31 | |
| Low | 1.22 | |
| Volume | 673,597 | |
| Change | 0.01 | |
| Change % | 0.40 | |
| Avg Volume (20 Days) | 795,266 | |
| Volume/Avg Volume (20 Days) Ratio | 0.85 | |
| 52 Week Range | 0.73 - 5.78 | |
| Price vs 52 Week High | -78.46% | |
| Price vs 52 Week Low | 70.55% | |
| Range | -1.84 | |
| Gap Up/Down | -0.01 | |
Fundamentals | ||
| Market Capitalization (Mln) | 118 | |
| EBIDTA | 34,057,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 4.00 | |
| Book Value | 2.1710 | |
| Earnings Per Share | -0.7750 | |
| EPS Estimate Current Quarter | -0.0400 | |
| EPS Estimate Next Quarter | -0.0600 | |
| EPS Estimate Current Year | -0.0700 | |
| EPS Estimate Next Year | 0.2000 | |
| Diluted EPS (TTM) | -0.7750 | |
| Revenues | ||
| Profit Marging | -0.2756 | |
| Operating Marging (TTM) | 0.0492 | |
| Return on asset (TTM) | 0.0107 | |
| Return on equity (TTM) | -0.3500 | |
| Revenue TTM | 109,708,000 | |
| Revenue per share TTM | 2.7840 | |
| Quarterly Revenue Growth (YOY) | -0.2630 | |
| Quarterly Earnings Growth (YOY) | -0.9410 | |
| Gross Profit (TTM) | 92,349,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 7.1480 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.6590 | |
| Revenue Enterprise Value | 0.7766 | |
| EBITDA Enterprise Value | 3.8676 | |
| Shares | ||
| Shares Outstanding | 44,634,100 | |
| Shares Float | 43,948,505 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 2.36 | |
| Institutions (%) | 14.59 | |
06/27 09:51 EST - seekingalpha.com
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval, providing a new opportunity with Rolvedon. A DCF valuation model suggests a fair equity value of $4.00 per share, indicating a potential 300% upside from the current share price, but high risks are involved.
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharmaceuticals saved Assertio from potential collapse after a generic drug approval, providing a new opportunity with Rolvedon. A DCF valuation model suggests a fair equity value of $4.00 per share, indicating a potential 300% upside from the current share price, but high risks are involved.
06/24 10:21 EST - 247wallst.com
3 Penny Stocks With 458% Average Upside According to Wall Street Analysts
Investors might be intrigued by penny stocks because they are so cheap to own. By investing $100 into a stock that trades for $0.50, you can own 200 shares of a company in your portfolio.
3 Penny Stocks With 458% Average Upside According to Wall Street Analysts
Investors might be intrigued by penny stocks because they are so cheap to own. By investing $100 into a stock that trades for $0.50, you can own 200 shares of a company in your portfolio.
06/06 16:05 EST - globenewswire.com
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective May 31, 2024, the Compensation Committee of the Company's Board of Directors granted the Company's new Chief Executive Officer, Brendan P. O'Grady, 500,000 restricted stock units (“RSUs”) and 1,800,000 stock options (“options”).
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective May 31, 2024, the Compensation Committee of the Company's Board of Directors granted the Company's new Chief Executive Officer, Brendan P. O'Grady, 500,000 restricted stock units (“RSUs”) and 1,800,000 stock options (“options”).
06/05 08:30 EST - globenewswire.com
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will present at the Sidoti Small Cap Conference, which will take place virtually on June 12, 2024.
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief Financial Officer, will present at the Sidoti Small Cap Conference, which will take place virtually on June 12, 2024.
05/17 09:15 EST - globenewswire.com
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024.
05/17 07:30 EST - prnewswire.com
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws NEW YORK , May 17, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), today released a letter from Rumbi B. Petrozzello, a Certified Public Accountant and Certified Fraud Examiner who previously served as President of the New York State Society of CPAs.
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws NEW YORK , May 17, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT), today released a letter from Rumbi B. Petrozzello, a Certified Public Accountant and Certified Fraud Examiner who previously served as President of the New York State Society of CPAs.
05/16 09:16 EST - globenewswire.com
Assertio to Participate in AGP Healthcare Conference on May 21
LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio's business at 3:40 p.m. Eastern Time.
Assertio to Participate in AGP Healthcare Conference on May 21
LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio's business at 3:40 p.m. Eastern Time.
05/13 17:52 EST - prnewswire.com
BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS
Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws Board and Management Inappropriately Answered or Refused to Answer Questions Over Very Material Matters Believes Insiders May Have Not Personally Purchased Shares in Over Three Years Due to Material Non-Public Information Last Remaining Investor-Minded Advocate on Board Has Chosen to Step Down Over Inappropriate Boardroom Activity, Leaving a Largely Out-of-Touch Board Analysts Have Dropped Coverage of Assertio Due to What Appears to be Lost Faith in Leadership's Due Diligence Abilities, Reinforcing BHG's Concerns Intends to Imminently Release Third-Party Expert Opinions Concerning Assertio Board and Management's Apparent Disclosure Failures and Deficiencies, for Further Delivery to Regulators Believes Board Should Promptly Explore Strategic Alternatives, Including a Possible Sale, Given Significant Opportunity to Achieve Post-Acquisition Operating Profit Enhancement through Reduced SG&A Expenses NEW YORK , May 13, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) urges Assertio stockholders to vote "against" all of the Company's director nominees at the Company's upcoming 2024 annual meeting of stockholders on May 23, 2024 (the "Annual Meeting"). BHG strongly believes that significant change to the Assertio board of directors (the "Board") is necessary in order to bring about new oversight and reinstate stockholder-like judgment in the Boardroom.
BUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERS
Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws Board and Management Inappropriately Answered or Refused to Answer Questions Over Very Material Matters Believes Insiders May Have Not Personally Purchased Shares in Over Three Years Due to Material Non-Public Information Last Remaining Investor-Minded Advocate on Board Has Chosen to Step Down Over Inappropriate Boardroom Activity, Leaving a Largely Out-of-Touch Board Analysts Have Dropped Coverage of Assertio Due to What Appears to be Lost Faith in Leadership's Due Diligence Abilities, Reinforcing BHG's Concerns Intends to Imminently Release Third-Party Expert Opinions Concerning Assertio Board and Management's Apparent Disclosure Failures and Deficiencies, for Further Delivery to Regulators Believes Board Should Promptly Explore Strategic Alternatives, Including a Possible Sale, Given Significant Opportunity to Achieve Post-Acquisition Operating Profit Enhancement through Reduced SG&A Expenses NEW YORK , May 13, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fund manager that holds a significant interest in the common stock shares of Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ: ASRT) urges Assertio stockholders to vote "against" all of the Company's director nominees at the Company's upcoming 2024 annual meeting of stockholders on May 23, 2024 (the "Annual Meeting"). BHG strongly believes that significant change to the Assertio board of directors (the "Board") is necessary in order to bring about new oversight and reinstate stockholder-like judgment in the Boardroom.
05/10 15:12 EST - globenewswire.com
Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference to be held May 13, 2024 in New York City.
Assertio to Present at the Citizens JMP Life Sciences Conference in New York City
LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference to be held May 13, 2024 in New York City.
05/06 19:07 EST - seekingalpha.com
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets Operator Good afternoon, and welcome to Assertio Holdings First Quarter 2024 Financial Results Call. [Operator Instructions] I would now like to turn the call over to Matt Kreps, Investor Relations for the company.
Assertio Holdings, Inc. (ASRT) Q1 2024 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT ) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Thomas Flaten - Lake Street Capital Markets Operator Good afternoon, and welcome to Assertio Holdings First Quarter 2024 Financial Results Call. [Operator Instructions] I would now like to turn the call over to Matt Kreps, Investor Relations for the company.
05/06 16:01 EST - globenewswire.com
Assertio Reports First Quarter 2024 Financial Results
First Quarter Net Product Sales of $31.9 Million
Assertio Reports First Quarter 2024 Financial Results
First Quarter Net Product Sales of $31.9 Million
04/25 08:00 EST - globenewswire.com
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
Assertio Holdings, Inc. to Report First Quarter 2024 Financial Results on May 6, 2024
LAKE FOREST, Ill., April 25, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will release first quarter 2024 financial results on Monday, May 6, 2024, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time.
04/01 09:00 EST - globenewswire.com
Assertio to Present at LD Micro Invitational Conference in New York City
LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
Assertio to Present at LD Micro Invitational Conference in New York City
LAKE FOREST, Ill., April 01, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the LD Micro Invitational XIV Conference to be held April 9, 2024 in New York City.
03/11 18:02 EST - seekingalpha.com
Assertio Holdings Inc. (ASRT) Q4 2023 Earnings Call Transcript
Assertio Holdings Inc. (NASDAQ:ASRT ) Q4 2023 Earnings Conference Call March 11, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Operator Thank you for standing by, and welcome to the Assertio Holdings Fourth Quarter and Full Year 2023 Results Call. I would now like to welcome Matt Kreps, Investor Relations for the company to begin the call.
Assertio Holdings Inc. (ASRT) Q4 2023 Earnings Call Transcript
Assertio Holdings Inc. (NASDAQ:ASRT ) Q4 2023 Earnings Conference Call March 11, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Heather Mason - Interim CEO Ajay Patel - CFO Paul Schwichtenberg - Chief Commercial Officer Conference Call Participants Thomas Flaten - Lake Street Capital Markets Jim Sidoti - Sidoti & Company Operator Thank you for standing by, and welcome to the Assertio Holdings Fourth Quarter and Full Year 2023 Results Call. I would now like to welcome Matt Kreps, Investor Relations for the company to begin the call.
03/11 16:01 EST - globenewswire.com
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million
Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter Net Product Sales $32.5 Million, Cash Flow from Operations of $5.7 Million
03/05 11:30 EST - accesswire.com
Assertio Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69322&wire=1 or contact Joseph E. Levi, Esq.
Assertio Holdings, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 5, 2024 to Discuss Your Rights - ASRT
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69322&wire=1 or contact Joseph E. Levi, Esq.
03/05 05:45 EST - prnewswire.com
The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT
NEW YORK , March 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Assertio Holdings, Inc.. Shareholders who purchased shares of ASRT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
The Gross Law Firm Notifies Assertio Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ASRT
NEW YORK , March 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Assertio Holdings, Inc.. Shareholders who purchased shares of ASRT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
03/05 04:40 EST - accesswire.com
Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69257&wire=1 or contact Joseph E. Levi, Esq.
Class Action Filed Against Assertio Holdings, Inc. (ASRT) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69257&wire=1 or contact Joseph E. Levi, Esq.
03/05 04:40 EST - accesswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 5, 2024 in Assertio Holdings Lawsuit - ASRT
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69255&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 5, 2024 in Assertio Holdings Lawsuit - ASRT
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69255&wire=1 or contact Joseph E. Levi, Esq.
03/04 17:30 EST - accesswire.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc.(ASRT) Shareholders
NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69171&wire=1 or contact Joseph E. Levi, Esq.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc.(ASRT) Shareholders
NEW YORK, NY / ACCESSWIRE / March 4, 2024 / If you suffered a loss on your Assertio Holdings, Inc. (NASDAQ:ASRT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/assertio-holdings-lawsuit-submission-form?prid=69171&wire=1 or contact Joseph E. Levi, Esq.